TISLELIZUMAB
Clinical trials for TISLELIZUMAB explained in plain language.
Never miss a new study
Get alerted when new TISLELIZUMAB trials appear
Sign up with your email to follow new studies for TISLELIZUMAB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple therapy offers hope for advanced lung cancer patients
Disease control Recruiting nowThis study is for people with advanced non-small cell lung cancer (stage IIIB/C-IV) who cannot tolerate standard chemoradiation. It tests a sequence of platinum-based chemotherapy, followed by a special type of radiation (hypofractionated radiotherapy), and then the immunotherapy…
Matched conditions: TISLELIZUMAB
Phase: PHASE2 • Sponsor: Zibo Municipal Hospital • Aim: Disease control
Last updated May 16, 2026 23:35 UTC
-
Gut bacteria boosts cancer treatment? new trial tests Probio-M9 in rectal cancer
Disease control Recruiting nowThis study tests whether adding a probiotic called Probio-M9 to standard chemoradiation and immunotherapy (tislelizumab) can help shrink rectal tumors before surgery. About 50 adults with locally advanced rectal cancer will be randomly assigned to receive the probiotic or a place…
Matched conditions: TISLELIZUMAB
Phase: PHASE2 • Sponsor: Seventh Medical Center of PLA General Hospital • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Kidney-Sparing drug combo offers hope for renal pelvic cancer patients
Disease control Recruiting nowThis study tests a combination of two drugs (tislelizumab and nab-paclitaxel) to treat a type of kidney cancer called renal pelvic cancer. The goal is to control the disease while saving the kidney, avoiding the need for full kidney removal. About 35 adults with early-stage cance…
Matched conditions: TISLELIZUMAB
Phase: PHASE2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New combo targets hidden cancer cells in colorectal patients
Disease control Recruiting nowThis study tests whether a combination of two drugs, fruquintinib and tislelizumab, can control colorectal cancer in people who have completed chemotherapy but still have signs of minimal residual disease (MRD) based on a sensitive blood test (ctDNA). About 20 adults with stable …
Matched conditions: TISLELIZUMAB
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:54 UTC